Sol-Gel Technologies Ltd. (SLGL)

NASDAQ: SLGL · IEX Real-Time Price · USD
4.27
+0.04 (1.07%)
Mar 24, 2023, 4:00 PM EDT - Market closed
1.07%
Market Cap 109.59M
Revenue (ttm) 3.88M
Net Income (ttm) -14.92M
Shares Out 25.70M
EPS (ttm) -0.65
PE Ratio n/a
Forward PE 9.34
Dividend n/a
Ex-Dividend Date n/a
Volume 61,815
Open 4.30
Previous Close 4.22
Day's Range 4.22 - 4.48
52-Week Range 3.24 - 7.95
Beta 1.32
Analysts Buy
Price Target 12.75 (+198.95%)
Earnings Date May 11, 2023

About SLGL

Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, w... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jan 23, 2018
Employees 53
Stock Exchange NASDAQ
Ticker Symbol SLGL
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for SLGL stock is "Buy." The 12-month stock price forecast is $12.75, which is an increase of 198.95% from the latest price.

Price Target
$12.75
(198.95% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Sol-Gel Technologies to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference

NESS ZIONA, Israel, March 20, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company with two innovative dermatology products that were launched in the U.S. and an i...

6 days ago - GlobeNewsWire

7 Biotech Stocks That Could Be the Next Big Thing

While the concept of high-risk speculation seems particularly dangerous at this juncture, gamblers may nevertheless want to consider the merits of targeting potentially lucrative biotech stocks that c...

1 week ago - InvestorPlace

Sol-Gel Technologies Ltd. (SLGL) Reports Q4 Loss, Lags Revenue Estimates

Sol-Gel Technologies Ltd. (SLGL) delivered earnings and revenue surprises of -92.31% and 94.60%, respectively, for the quarter ended December 2022.

2 weeks ago - Zacks Investment Research

Sol-Gel Reports Full-Year 2022 Financial Results and Corporate Developments

NESS ZIONA, Israel, March 10, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company with two innovative dermatology products that were launched in the U.S. and an i...

2 weeks ago - GlobeNewsWire

The Top 7 Penny Stocks to Invest in for the Long-Term

Typically, penny stocks represent pure market wagers appropriate only for hardened gamblers. However, every once in a blue moon, a few ideas pop up in this segment that may be worth a genuine investme...

1 month ago - InvestorPlace

Sol-Gel Announces Aggregate $22.8 Million Concurrent Registered Direct and Private Placement Offerings

NESS ZIONA, Israel, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a dermatology company with FDA approvals for EPSOLAY® and TWYNEO®, two inn...

2 months ago - GlobeNewsWire

Sol-Gel Acquires Patidegib, a Phase 3, FDA-Breakthrough-Designated Orphan Product Candidate to Pursue Potential Market of Over $300 Million

NESS ZIONA, Israel, Jan. 27, 2023 (GLOBE NEWSWIRE) --  Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company with FDA approvals for EPSOLAY® and TWYNEO®, two innovative dermatology products...

2 months ago - GlobeNewsWire

3 Generic Drug Stocks to Watch Amid Inflation Pressures

The impact of inflationary headwinds and pricing pressure on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to AMPH, RDY and SLGL.

Other symbols: AMPHRDY
3 months ago - Zacks Investment Research

SolGel Technologies Ltd. (SLGL) Reports Q3 Loss, Misses Revenue Estimates

SolGel Technologies Ltd. (SLGL) delivered earnings and revenue surprises of -114.29% and 92.44%, respectively, for the quarter ended September 2022.

4 months ago - Zacks Investment Research

Sol-Gel Technologies Reports Third Quarter 2022 Financial Results and Provides Corporate Update

NESS ZIONA, Israel, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and gen...

4 months ago - GlobeNewsWire

Sol-Gel Technologies Appoints Michael Glezin Vice President, Business Development

NESS ZIONA, Israel, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and gen...

6 months ago - GlobeNewsWire

3 Generic Drug Stocks to Watch Amid Continued Pricing Pressure

The impact of COVID-19 and pricing pressure on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to TEVA, RDY and SLGL.

Other symbols: RDYTEVA
7 months ago - Zacks Investment Research

SolGel Technologies Ltd. (SLGL) Reports Q2 Loss, Misses Revenue Estimates

SolGel Technologies Ltd. (SLGL) delivered earnings and revenue surprises of 90% and 27.46%, respectively, for the quarter ended June 2022.

8 months ago - Zacks Investment Research

Sol-Gel Technologies Reports Second Quarter 2022 Financial Results and Provides Corporate Update

NESS ZIONA, Israel, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and gen...

8 months ago - GlobeNewsWire

SolGel Technologies Ltd. (SLGL) Reports Q1 Loss, Misses Revenue Estimates

SolGel Technologies Ltd. (SLGL) delivered earnings and revenue surprises of 20% and 99.85%, respectively, for the quarter ended March 2022.

11 months ago - Zacks Investment Research

Sol-Gel Technologies Reports First Quarter 2022 Financial Results and Provides Corporate Update

NESS ZIONA, Israel, May 13, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and gene...

11 months ago - GlobeNewsWire

Earnings Preview: SolGel Technologies Ltd. (SLGL) Q1 Earnings Expected to Decline

SolGel Technologies Ltd. (SLGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

11 months ago - Zacks Investment Research

Sol-Gel Technologies and Galderma Announce FDA Approval of EPSOLAY®

NESS ZIONA, Israel and ZUG, Switzerland, April 25, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing and commercializing bran...

11 months ago - GlobeNewsWire

Sol-Gel Technologies Announces the Commercial Availability of TWYNEO®

NESS ZIONA, Israel, April 14, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topic...

1 year ago - GlobeNewsWire

Sol-Gel Technologies Reports Full Year 2021 Financial Results and Corporate Developments

NESS ZIONA, Israel, March 30, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topic...

1 year ago - GlobeNewsWire

Sol-Gel Technologies Announces U.S. Commercial Partner Galderma to Promote TWYNEO® at the American Academy of Dermatology Annual Meeting to be Held March 25-29 in Boston, MA

TWYNEO will be officially launched for commercial availability in Spring 2022. TWYNEO will be officially launched for commercial availability in Spring 2022.

1 year ago - GlobeNewsWire

Sol-Gel Technologies to Participate in Upcoming LifeSci Partners Corporate Access Event and H.C. Wainwright BioConnect 2022 Healthcare Conference

NESS ZIONA, Israel, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and...

1 year ago - GlobeNewsWire

Sol-Gel Technologies Announces Positive Update Related to FDA Review Status of EPSOLAY®

NESS ZIONA, Israel, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topica...

1 year ago - GlobeNewsWire

Sol-Gel Technologies Reports Third Quarter 2021 Financial Results and Highlights Recent Corporate Developments

NESS ZIONA, Israel, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topica...

1 year ago - GlobeNewsWire

Sol-Gel Technologies to Present Live at Jefferies London Healthcare Conference

NESS ZIONA, Israel, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topica...

1 year ago - GlobeNewsWire